ArticleScientific reports2015
Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Co-Inhibition of Kv1.3 Channel Activity by Selected Chalcones and Statins in a Model of Cancer Cell Line Jurkat T.Molecules (Basel, Switzerland) · 2026Article
- Pleiotropic Effects of Statins: Focus on Inflammation, Oxidative Stress and Immunomodulation (Part I).Current atherosclerosis reports · 2026Review
- Statins as Modulators of Epithelial to Mesenchymal Transition in Cardiovascular-Kidney-Metabolic Syndrome: a Comprehensive Review of Mechanisms and Therapeutic Implications.Current atherosclerosis reports · 2025Review
- An optimized Langendorff-free isolating method and electrophysiology studies for adult mouse atrioventricular node cells.BMC cardiovascular disorders · 2025Article
- Impact of statin therapy on CD40:CD40L signaling: mechanistic insights and therapeutic opportunities.Pharmacological reports : PR · 2025Review
- The role of potassium ion channels in chronic sinusitis.Frontiers in pharmacology · 2024Review
- Association of HMGCR inhibition with rheumatoid arthritis: a Mendelian randomization and colocalization study.Frontiers in endocrinology · 2023Article
- The toxin mimic FS48 from the salivary gland of Xenopsylla cheopis functions as a Kv1.3 channel-blocking immunomodulator of T cell activation.The Journal of biological chemistry · 2022Article
- Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells.Journal of molecular structure · 2021Article
- Article
- Pleiotropic Effects of Simvastatin on the Regulation of Potassium Channels in Monocytes.Frontiers in pharmacology · 2020Article
- High concentrations of atorvastatin reduce in-vitro function of conventional T and regulatory T cells.Clinical and experimental immunology · 2019Article
- High-Throughput Assessment of Mechanistic Toxicity of Chemicals in Miniaturized 3D Cell Culture.Current protocols in toxicology · 2019Article
- Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer.Frontiers in oncology · 2019Review
- Blockade of Transient Receptor Potential Vanilloid 4 Enhances Antioxidation after Myocardial Ischemia/Reperfusion.Oxidative medicine and cellular longevity · 2019Article
- A Kv1.3 channel-specific blocker alleviates neurological impairment through inhibiting T-cell activation in experimental autoimmune encephalomyelitis.CNS neuroscience & therapeutics · 2018Article
- High-content imaging assays on a miniaturized 3D cell culture platform.Toxicology in vitro : an international journal published in association with BIBRA · 2018Article
- Immune modulatory effects of statins.Immunology · 2018Review
- Differential Activity of Voltage- and CaFrontiers in physiology · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lovastatin is a member of Statins, which are beneficial in a lot of immunologic cardiovascular diseases and T cell-mediated autoimmune diseases. Kv1.3 channel plays important roles in the activation and proliferation of T cells, and have become attractive target for immune-related disorders. The present study was designed to examine the block effect of Lovastatin on Kv1.3 channel in human T cells, and to clarify its new immunomodulatory mechanism. We found that Lovastatin inhibited Kv1.3 currents in a concentration- and voltage-dependent manner, and the IC50 for peak, end of the pulse was 39.81 ± 5.11, 6.92 ± 0.95 μM, respectively. Lovastatin also accelerated the decay rate of current inactivation and negatively shifted the steady-state inactivation curves concentration-dependently, without affecting the activation curve. However, 30 μM Lovastatin had no apparent effect on KCa current in human T cells. Furthermore, Lovastatin inhibited Ca(2+) influx, T cell proliferation as well as IL-2 production. The activities of NFAT1 and NF-κB p65/50 were down-regulated by Lovastatin, too. At last, Mevalonate application only partially reversed the inhibition of Lovastatin on IL-2 secretion, and the siRNA against Kv1.3 also partially reduced this inhibitory effect of Lovastatin. In conclusion, Lovastatin can exert immunodulatory properties through the new mechanism of blocking Kv1.3 channel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.